Biotech Archives - Page 728 of 733

1 minute read

Needham Cuts Price Target On This NASH-Focused Stock As Its Awaits Visibility On Regulatory Path

July 8, 12:53 PM

Yesterday, Intercept Pharmaceuticals Inc (NASDAQ:ICPT) announced data from the new interim analysis of the Phase 3 REGENERATE trial evaluating obeticholic acid in…

ICPT

1 minute read

Why This Small-Cap Stock Is Gaining More Than 10% Today?

By Vandana Singh

July 8, 11:40 AM

Chardan has initiated coverage of Immuneering Corp (NASDAQ:IMRX) with a Buy rating and a price target of $18. Immuneering’s lead candidate, IMM-1-104, an…

IMRX

1 minute read

AbbVie Dumps An Early-Alzheimer’s Candidate Developing In Collaboration With Alector

By Vandana Singh

July 8, 10:54 AM

AbbVie Inc (NYSE:ABBV) has decided to terminate the CD33 collaboration program with Alector Inc (NASDAQ:ALEC), developing AL003 for Alzheimer’s disease as one of…

ABBV

1 minute read

Horizon Therapeutics Receives FDA Approval For Uncontrolled Gout Candidate

By Ragothaman Srinivasan

July 8, 9:03 AM

The U.S. Food and Drug Administration (FDA) has approved Horizon Therapeutics’ (NASDAQ: HZNP) supplemental Biologics License Application (sBLA) for expanding the labeling to include KRYSTEXXA (pegloticase) injection co-administered with methotrexate, in patients with uncontrolled gout.

HZNP

3 minute read

The Daily Biotech Pulse: Pfizer Inks Pact With Africa For COVID-19 Pills, Emergent Bio & Ridgeback To Increase Access To Ebola Treatment, ADC Therapeutics & Sobi In European Pact For Lymphoma Drug

By Vandana Singh

July 8, 8:19 AM

Here's a roundup of top developments in the biotech space over the last 24 hours:

ADCT

1 minute read

ADC Therapeutics, Sobi Ink European Licensing Pact For Lymphoma Drug

By Vandana Singh

July 8, 7:20 AM

ADC Therapeutics SA (NYSE:ADCT) has entered into an exclusive license agreement with Swedish Orphan Biovitrum AB (OTC:BIOVF) for the development and commercialization of…

ADCT

3 minute read

Optinose Announces Additional Results From ReOpen2 And Initial Results From Pooled Analyses Of Both Trials In The ReOpen Program

By Bill Haddad

July 8, 7:02 AM

Company previously announced positive top-line results from both ReOpen1 and ReOpen2, the landmark trials evaluating XHANCE as a treatment for chronic sinusitis Multiple secondary endpoints from ReOpen2 indicate

OPTN

1 minute read

RVL Pharma Issues Interim Q2 Sales From Its Droopy Eye Treatment

By Vandana Singh

July 8, 6:33 AM

RVL Pharmaceuticals plc (NASDAQ:RVLP) announced preliminary Q2 FY22 sales from Upneeq of $8.4 million, up 42% sequentially. Upneeq (oxymetazoline hydrochloride…

RVLP

1 minute read

Inventiva Announces The Screening Of The First Patient In LEGEND, A Phase IIa Combination Trial With Lanifibranor And Empagliflozin In Patients With NASH And T2D

By Benzinga Newsdesk

July 7, 4:01 PM

The Phase IIa Proof-of-Concept study is designed to assess the safety and efficacy of lanifibranor in combination with the SGLT2 inhibitor empagliflozin for the treatment of patients with non-cirrhotic non-alcoholic

IVA

2 minute read

Atai Life Sciences: Capital Raise, Share Options, Cathy Wood And More On Biotech Psychedelics Leader

By Lara Goldstein

July 7, 3:14 PM

Atai Life Sciences N.V.

ARKG